Teva Must Surrender Generics To Get Cephalon: FTC
The rights and assets of the generic versions of Teva's cancer pain drug, Actiq, and muscle relaxant, Flexeril, must be sold to New Jersey-based generic drug manufacturer Par Pharmaceutical Inc. within 10 days of the acquisition, the FTC said.
In addition, the commission will require Teva to...
Already a subscriber? Click here to login